Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced its launch with an initial $100 million in financing led by ARCH Venture Partners, Mubadala Capital and Monograph Capital. Ollin is assembling a robust pipeline of both clinical and late-stage preclinical programs, building upon validated biologies to better address unmet treatment needs in ophthalmology.
